Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress.

NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients. In the final ...

Get detailed information on Ribociclib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

This can lead to the need for patients to stop receiving the drug altogether or start requiring a lower dosage, but we don’t generally see that with ENHERTU. "There's no real cumulative side effect," ...

Verapamil is a prescription medication available under the brand name Verelan and as a generic drug. While not approved by the U.S. Food and Drug Administration (FDA) for migraine prevention, it may ...